HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
OUST
Ouster, Inc.
OUST lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
OUST Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
OUST's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
OUST PE Valuation
OUST has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
OUST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
OUST has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
OUST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.65 | +$0.98 |
| Q2 2026 | -$0.82 | +$0.98 |
| Q1 2026 | -$0.93 | +$1.02 |
| Q4 2025 | -$1.07 | +$1.01 |
| Q3 2025 | -$1.63 | +$0.98 |
| Q2 2025 | -$1.80 | +$1.16 |
| Q1 2025 | -$1.95 | +$3.67 |
| Q4 2024 | -$2.08 | +$9.02 |
OUST has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over OUST on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over OUST on profitability, with a higher operating margin.
OUST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $59.3M | +50% |
| Q2 2026 | $54.6M | +56% |
| Q1 2026 | $48.6M | +49% |
| Q4 2025 | $62.2M | +107% |
| Q3 2025 | $39.5M | +41% |
| Q2 2025 | $35M | +30% |
| Q1 2025 | $32.6M | +26% |
| Q4 2024 | $30.1M | +23% |
OUST's revenue has grown year over year for 15 quarters in a row: $59M last quarter, up 50% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -32% | +29 points |
| Q2 2026 | -37% | +40 points |
| Q1 2026 | -40% | +34 points |
| Q4 2025 | 1.4% | +87 points |
| Q3 2025 | -61% | +37 points |
| Q2 2025 | -77% | +17 points |
| Q1 2025 | -73% | +27 points |
| Q4 2024 | -85% | +68 points |
OUST's operating margin was −32% last quarter, up 29 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over OUST on cash generation, producing positive trailing cash flow while its opponent burns cash.
OUST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$35M | -$15M |
| Q2 2026 | -$15.4M | -$13.2M |
| Q1 2026 | -$9.8M | -$4.4M |
| Q4 2025 | -$37.2M | -$33.2M |
| Q3 2025 | -$20M | -$15.7M |
| Q2 2025 | -$2.2M | +$19.8M |
| Q1 2025 | -$5.4M | +$1.7M |
| Q4 2024 | -$4M | +$20.6M |
OUST has burned cash in almost every quarter: −$97M over the past year, against −$32M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over OUST on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
OUST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8.3% | +5.5M shares |
| 1 year | +23% | +13.5M shares |
| 3 years | +82% | +32.2M shares |
| 5 years | +1183% | +65.9M shares |
| Available history | +6407% | +70.4M shares |
OUST has 71M diluted shares, up 23% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $1,000 |
| Q3 2022 | $3,000 |
| Q2 2022 | $12,000 |
| Q1 2022 | $31,000 |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
OUST Net Leverage
OUST's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
OUST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.2 | Neutral |
| Stochastic | 26.0 | Neutral |
OUST's weekly RSI is 51 (neutral) and its Stochastic is 26 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
OUST PE vs Technology Sector
OUST has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
OUST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.9 | 1.9% above |
| 20 week MA | $38.1 | 4% below |
| 50 week MA | $31.3 | 17% above |
| 100 week MA | $24.9 | 47% above |
| 200 week MA | $16.3 | 125% above |
OUST has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
OUST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $97.0 | $162.5 | +68% |
| 2021 | $162.5 | $53.8 | -67% |
| 2022 | $53.8 | $8.88 | -83% |
| 2023 | $8.88 | $7.67 | -14% |
| 2024 | $7.67 | $12.5 | +63% |
| 2025 | $12.5 | $22.0 | +76% |
| 2026 YTD | $22.0 | $36.6 | +67% |
OUST has the edge over HIMS on returns for 2026, with the stronger performance.